Pendemic create oppoturnity. E_老虎社区_美港股上老虎

超群yibo
2021-09-03

Pendemic create oppoturnity. Endemic creat revenue.

FDA Weighing Dose of Moderna Covid-19 Booster

Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots.

FDA Weighing Dose of Moderna Covid-19 Booster

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":815328317,"tweetId":"815328317","gmtCreate":1630646984939,"gmtModify":1631889976203,"author":{"id":3576231291459124,"idStr":"3576231291459124","authorId":3576231291459124,"authorIdStr":"3576231291459124","name":"超群yibo","avatar":"https://static.tigerbbs.com/6594cf6901beda8fdf0f00a0e5853f18","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pendemic create oppoturnity. Endemic creat revenue.</p></body></html>","htmlText":"<html><head></head><body><p>Pendemic create oppoturnity. Endemic creat revenue.</p></body></html>","text":"Pendemic create oppoturnity. Endemic creat revenue.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/815328317","repostId":1194913620,"repostType":4,"repost":{"id":"1194913620","kind":"news","pubTimestamp":1630637588,"share":"https://www.laohu8.com/m/news/1194913620?lang=&edition=full","pubTime":"2021-09-03 10:53","market":"us","language":"en","title":"FDA Weighing Dose of Moderna Covid-19 Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=1194913620","media":"The Wall Street Journal","summary":"Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots.\n\n","content":"<blockquote>\n <b>Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots.</b>\n</blockquote>\n<p>The Food and Drug Administration is considering whether to authorize a lower dose ofModernaInc.’sCovid-19 vaccine for boostersthan the dose given in the first two shots, people familiar with the deliberations said.</p>\n<p>Moderna said Wednesday it is asking the FDA to authorize a 50 microgram dose, half the dosage of the first two shots. Some in the government are leaning toward authorizing the 100 microgram dose, the people said, because of concerns a lower-dose booster might not offer a durable enough boost to counterfast-changing variants of Covid-19.</p>\n<p>No final decision has been made, the people said, as the FDA is still reviewing data from studies that tested boosters using the different doses. People who have seen the data said both doses produce a strong immune response.</p>\n<p>Complicating the decision is the fact that the FDA has limited comparative data on which to base their choice, one person familiar with the discussions said.</p>\n<p>The continuing deliberations are a reason the agency hasn’t yet authorized boosters, though the people expect a decision soon.</p>\n<p>One possible benefit of a lower dose is fewer side effects, people familiar with the matter said.</p>\n<p>Last month, the Biden administration recommended that adults who got a messenger RNA vaccine from either Moderna orPfizerInc.and partnerBioNTech SEstartgetting boosters this month.</p>\n<p>Johnson &amp; Johnson’svaccine is also expected to be included in the boosting strategy,after releasing the first resultsabout its boosters last month. The company said it is engaging with the FDA.</p>\n<p>There is no debate about the booster doses to administer for the Pfizer-BioNTech or J&amp;J vaccines, one of the people said, though a decision on the J&amp;J booster might take longer. Their boosters will be the same doses as the first shots, the person said.</p>\n<p>After initially spurning talk about boosters, federal health officials embraced the idea as the contagious Delta variant drove up case counts, even among some peoplewho were vaccinated.</p>\n<p>Also contributing to the change of mind was emerging but inconclusive evidence, from researchers in Israel and elsewhere, suggesting the molecular defenses triggered by vaccinationwanes after several months.</p>\n<p>Whether boosters are needed remains up for debate. Some researchers say the evidence is insufficient, while the World Health Organization has urged giving shots to peoplein countries with limited supplies.</p>\n<p>Moderna and the National Institutes of Health tested both 50 mcg and 100 mcg booster doses in clinical trials.</p>\n<p>Last month, Modernareleased initial datashowing that a 50 mcg booster strengthened antibodies against Delta and other variants of concern significantly higher than the levels after trial subjects received their two initial doses.</p>\n<p>The Cambridge, Mass., company has been urging the FDA in recent weeks to authorize a 50 mcg booster, according to people familiar with the matter and a statement announcing its submission on Wednesday.</p>\n<p>The company declined to answer questions early this week about its talks with the FDA, before issuing a statement, saying it had applied for the booster dose authorization at the 50 mcg level.</p>\n<p>Authorization of a lower dose would allow Moderna to manufacture up to three billion boosters next year, as many as one billion more than it could make of the higher dose.</p>\n<p>Yet it would pose several logistical challenges, another person familiar with the discussions said.</p>\n<p>The different dosages may cause confusion at vaccination sites, the people said. Pharmacists would have to prepare the doses in different ways. Nurses would have to be careful to give people the right dose.</p>\n<p>Another issue, the person said, is a lower dose would lead to some wasted vaccine, at least until new, smaller vials begin arriving in October.</p>\n<p>Current Moderna vials contain enough vaccine for 14 100 mcg doses, but not all of that could be used for smaller doses because the vials can only be entered a certain number of times.</p>\n<p>The U.S. has ordered smaller vials already because they are easier for doctors’ offices and other providers to administer, the person said.</p>\n<p>It couldn’t be determined why people getting a Moderna booster might need a lower dose than people getting another manufacturer’s vaccine.</p>\n<p>Astudy of Belgian healthcare workerspublished Monday in a letter to the Journal of American Medical Association found that Moderna’s vaccine created twice as many antibodies as the Pfizer-BioNTech vaccine.</p>\n<p>The researchers said the difference might be explained by the higher mRNA content in Moderna’s vaccine as compared with Pfizer-BioNTech’s, as well as the week longer interval between shots for the Moderna vaccine.</p>\n<p>U.S. health officials are still figuring out the timing of exactly when people will be eligible to receive boosters.</p>\n<p>Federal health officials initially said it would be eight months after people have received two doses. The Wall Street Journal has reported the FDA is likelyto authorize boosters at six months.</p>\n<p>President Biden said last week that his administration is weighing whether to begin before eight months, perhaps as early as five months.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Weighing Dose of Moderna Covid-19 Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Weighing Dose of Moderna Covid-19 Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 10:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/fda-weighing-dose-of-moderna-covid-19-booster-11630593980?mod=business_lead_pos5><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots.\n\nThe Food and Drug Administration is considering whether to authorize a lower dose ofModernaInc.’...</p>\n\n<a href=\"https://www.wsj.com/articles/fda-weighing-dose-of-moderna-covid-19-booster-11630593980?mod=business_lead_pos5\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/fda-weighing-dose-of-moderna-covid-19-booster-11630593980?mod=business_lead_pos5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194913620","content_text":"Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots.\n\nThe Food and Drug Administration is considering whether to authorize a lower dose ofModernaInc.’sCovid-19 vaccine for boostersthan the dose given in the first two shots, people familiar with the deliberations said.\nModerna said Wednesday it is asking the FDA to authorize a 50 microgram dose, half the dosage of the first two shots. Some in the government are leaning toward authorizing the 100 microgram dose, the people said, because of concerns a lower-dose booster might not offer a durable enough boost to counterfast-changing variants of Covid-19.\nNo final decision has been made, the people said, as the FDA is still reviewing data from studies that tested boosters using the different doses. People who have seen the data said both doses produce a strong immune response.\nComplicating the decision is the fact that the FDA has limited comparative data on which to base their choice, one person familiar with the discussions said.\nThe continuing deliberations are a reason the agency hasn’t yet authorized boosters, though the people expect a decision soon.\nOne possible benefit of a lower dose is fewer side effects, people familiar with the matter said.\nLast month, the Biden administration recommended that adults who got a messenger RNA vaccine from either Moderna orPfizerInc.and partnerBioNTech SEstartgetting boosters this month.\nJohnson & Johnson’svaccine is also expected to be included in the boosting strategy,after releasing the first resultsabout its boosters last month. The company said it is engaging with the FDA.\nThere is no debate about the booster doses to administer for the Pfizer-BioNTech or J&J vaccines, one of the people said, though a decision on the J&J booster might take longer. Their boosters will be the same doses as the first shots, the person said.\nAfter initially spurning talk about boosters, federal health officials embraced the idea as the contagious Delta variant drove up case counts, even among some peoplewho were vaccinated.\nAlso contributing to the change of mind was emerging but inconclusive evidence, from researchers in Israel and elsewhere, suggesting the molecular defenses triggered by vaccinationwanes after several months.\nWhether boosters are needed remains up for debate. Some researchers say the evidence is insufficient, while the World Health Organization has urged giving shots to peoplein countries with limited supplies.\nModerna and the National Institutes of Health tested both 50 mcg and 100 mcg booster doses in clinical trials.\nLast month, Modernareleased initial datashowing that a 50 mcg booster strengthened antibodies against Delta and other variants of concern significantly higher than the levels after trial subjects received their two initial doses.\nThe Cambridge, Mass., company has been urging the FDA in recent weeks to authorize a 50 mcg booster, according to people familiar with the matter and a statement announcing its submission on Wednesday.\nThe company declined to answer questions early this week about its talks with the FDA, before issuing a statement, saying it had applied for the booster dose authorization at the 50 mcg level.\nAuthorization of a lower dose would allow Moderna to manufacture up to three billion boosters next year, as many as one billion more than it could make of the higher dose.\nYet it would pose several logistical challenges, another person familiar with the discussions said.\nThe different dosages may cause confusion at vaccination sites, the people said. Pharmacists would have to prepare the doses in different ways. Nurses would have to be careful to give people the right dose.\nAnother issue, the person said, is a lower dose would lead to some wasted vaccine, at least until new, smaller vials begin arriving in October.\nCurrent Moderna vials contain enough vaccine for 14 100 mcg doses, but not all of that could be used for smaller doses because the vials can only be entered a certain number of times.\nThe U.S. has ordered smaller vials already because they are easier for doctors’ offices and other providers to administer, the person said.\nIt couldn’t be determined why people getting a Moderna booster might need a lower dose than people getting another manufacturer’s vaccine.\nAstudy of Belgian healthcare workerspublished Monday in a letter to the Journal of American Medical Association found that Moderna’s vaccine created twice as many antibodies as the Pfizer-BioNTech vaccine.\nThe researchers said the difference might be explained by the higher mRNA content in Moderna’s vaccine as compared with Pfizer-BioNTech’s, as well as the week longer interval between shots for the Moderna vaccine.\nU.S. health officials are still figuring out the timing of exactly when people will be eligible to receive boosters.\nFederal health officials initially said it would be eight months after people have received two doses. The Wall Street Journal has reported the FDA is likelyto authorize boosters at six months.\nPresident Biden said last week that his administration is weighing whether to begin before eight months, perhaps as early as five months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":471,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":46,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

FDA Weighing Dose of Moderna Covid-19 Booster

评论（2）

热议股票